Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate

2013 ◽  
Vol 41 (3) ◽  
pp. 505-510 ◽  
Author(s):  
Amir Sabet ◽  
Khaled Ezziddin ◽  
Ulrich-Frank Pape ◽  
Karl Reichman ◽  
Torjan Haslerud ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Accurate Assessment ◽  
Peptide Receptor

Tu1923 Long-Term Survival Data in Progressing Advanced Midgut Neuroendocrine Tumours Following Peptide Receptor Radionuclide Therapy

2015 ◽  
Vol 148 (4) ◽  
pp. S-936
Author(s):  
Mehmet Yalchin ◽  
Amelia Oliveira ◽  
Deborah Pencharz ◽  
Shaunak Navalkissoor ◽  
Ann-Marie Quigley ◽  
...  
Keyword(s):  
Survival Data ◽  
Radionuclide Therapy ◽  
Neuroendocrine Tumours ◽  
Peptide Receptor Radionuclide Therapy ◽  
Term Survival ◽  
Long Term Survival ◽  
Peptide Receptor

scholarly journals Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate

2011 ◽  
Vol 52 (8) ◽  
pp. 1197-1203 ◽  
Author(s):  
S. Ezziddin ◽  
A. Sabet ◽  
F. Heinemann ◽  
C. J. Yong-Hing ◽  
H. Ahmadzadehfar ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor

scholarly journals Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide

Theranostics ◽  
2012 ◽  
Vol 2 (5) ◽  
pp. 472-480 ◽  
Author(s):  
Ebrahim S. Delpassand ◽  
Amin Samarghandi ◽  
Jennifer Sims Mourtada ◽  
Sara Zamanian ◽  
Gregory D. Espenan ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Toxicity Profile ◽  
Term Survival ◽  
Peptide Receptor ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Pet Ct Scan

scholarly journals Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate

2013 ◽  
Vol 54 (11) ◽  
pp. 1857-1861 ◽  
Author(s):  
A. Sabet ◽  
K. Ezziddin ◽  
U.-F. Pape ◽  
H. Ahmadzadehfar ◽  
K. Mayer ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor

scholarly journals Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience

2019 ◽  
Vol 8 (5) ◽  
pp. 528-535 ◽  
Author(s):  
G Giuffrida ◽  
F Ferraù ◽  
R Laudicella ◽  
O R Cotta ◽  
E Messina ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Radionuclide Therapy ◽  
Therapeutic Option ◽  
Pituitary Tumors ◽  
Peptide Receptor Radionuclide Therapy ◽  
Tumor Shrinkage ◽  
Long Term Outcome ◽  
Peptide Receptor ◽  
Giant Prolactinoma

In aggressive pituitary tumors (PT) showing local invasion or growth/recurrence despite multimodal conventional treatment, temozolomide (TMZ) is considered a further therapeutic option, while little data are available on peptide receptor radionuclide therapy (PRRT). We analyzed PRRT effectiveness, safety and long-term outcome in three patients with aggressive PT, also reviewing the current literature. Patient #1 (F, giant prolactinoma) received five cycles (total dose 37 GBq) of 111In-DTPA-octreotide over 23 months, after unsuccessful surgery and long-term dopamine-agonist treatment. Patient #2 (M, giant prolactinoma) underwent two cycles (12.6 GBq) of 177Lu-DOTATOC after multiple surgeries, radiosurgery and TMZ. In patient #3 (F, non-functioning PT), five cycles (29.8 GBq) of 177Lu-DOTATOC followed five surgeries, radiotherapy and TMZ. Eleven more cases of PRRT-treated aggressive PT emerged from literature. Patient #1 showed tumor shrinkage and visual/neurological amelioration over 8-year follow-up, while the other PTs continued to grow causing blindness and neuro-cognitive disorders (patient #2) or monolateral amaurosis (patient #3). No adverse effects were reported. Including the patients from literature, 4/13 presented tumor shrinkage and clinical/biochemical improvement after PRRT. Response did not correlate with patients’ gender or age, neither with used radionuclide/peptide, but PRRT failure was significantly associated with previous TMZ treatment. Overall, adverse effects occurred only in two patients. PRRT was successful in 1/3 of patients with aggressive PT, and in 4/5 of those not previously treated with TMZ, representing a safe option after unsuccessful multimodal treatment. However, at present, considering the few data, PRRT should be considered only in an experimental setting.

Sign in / Sign up

Export Citation Format

Share Document